ROCHE TRUMPETS DATA FOR SOLIRIS RIVAL IN NMOSD AFTER US, EU FILINGS

Roche has new positive data for its IL-6 targeting antibody satralizumab for neuromyelitis optica spectrum disorder (NMOSD), with regulatory decisions expected in 2020 as it prepares to go head-to-head with Alexion’s Soliris. NMOSD is an autoimmune disease that affects the central nervous system, and is characterised by progressive damage to neurons during relapses that can lead to blindness and paralysis
Read more...

;